Logo image of ALGS

ALIGOS THERAPEUTICS INC (ALGS) Stock Fundamental Analysis

NASDAQ:ALGS - Nasdaq - US01626L2043 - Common Stock - Currency: USD

18.63  -2.22 (-10.65%)

After market: 19.5 +0.87 (+4.67%)

Fundamental Rating

2

ALGS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. The financial health of ALGS is average, but there are quite some concerns on its profitability. ALGS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALGS had negative earnings in the past year.
ALGS had a negative operating cash flow in the past year.
ALGS had negative earnings in each of the past 5 years.
In the past 5 years ALGS always reported negative operating cash flow.
ALGS Yearly Net Income VS EBIT VS OCF VS FCFALGS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

ALGS's Return On Assets of -87.03% is on the low side compared to the rest of the industry. ALGS is outperformed by 71.05% of its industry peers.
ALGS's Return On Equity of -153.61% is on the low side compared to the rest of the industry. ALGS is outperformed by 65.36% of its industry peers.
Industry RankSector Rank
ROA -87.03%
ROE -153.61%
ROIC N/A
ROA(3y)-59.28%
ROA(5y)-50.89%
ROE(3y)-85.72%
ROE(5y)-70.21%
ROIC(3y)N/A
ROIC(5y)N/A
ALGS Yearly ROA, ROE, ROICALGS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

ALGS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALGS Yearly Profit, Operating, Gross MarginsALGS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K -2.5K

More info and screens

4

2. Health

2.1 Basic Checks

ALGS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALGS has less shares outstanding
ALGS has less shares outstanding than it did 5 years ago.
ALGS has a better debt/assets ratio than last year.
ALGS Yearly Shares OutstandingALGS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
ALGS Yearly Total Debt VS Total AssetsALGS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

ALGS has an Altman-Z score of -10.10. This is a bad value and indicates that ALGS is not financially healthy and even has some risk of bankruptcy.
ALGS has a Altman-Z score of -10.10. This is in the lower half of the industry: ALGS underperforms 73.53% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ALGS is not too dependend on debt financing.
The Debt to Equity ratio of ALGS (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.1
ROIC/WACCN/A
WACC9.5%
ALGS Yearly LT Debt VS Equity VS FCFALGS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 3.81 indicates that ALGS has no problem at all paying its short term obligations.
With a Current ratio value of 3.81, ALGS perfoms like the industry average, outperforming 45.12% of the companies in the same industry.
A Quick Ratio of 3.81 indicates that ALGS has no problem at all paying its short term obligations.
With a Quick ratio value of 3.81, ALGS perfoms like the industry average, outperforming 46.71% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.81
Quick Ratio 3.81
ALGS Yearly Current Assets VS Current LiabilitesALGS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 71.77% over the past year.
ALGS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -63.41%.
EPS 1Y (TTM)71.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.05%
Revenue 1Y (TTM)-63.41%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-60.82%

3.2 Future

The Earnings Per Share is expected to grow by 13.19% on average over the next years. This is quite good.
Based on estimates for the next years, ALGS will show a very strong growth in Revenue. The Revenue will grow by 75.34% on average per year.
EPS Next Y72.97%
EPS Next 2Y30.16%
EPS Next 3Y18.47%
EPS Next 5Y13.19%
Revenue Next Year-74.03%
Revenue Next 2Y-69.6%
Revenue Next 3Y-25.99%
Revenue Next 5Y75.34%

3.3 Evolution

ALGS Yearly Revenue VS EstimatesALGS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ALGS Yearly EPS VS EstimatesALGS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 50 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALGS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALGS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALGS Price Earnings VS Forward Price EarningsALGS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALGS Per share dataALGS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20

4.3 Compensation for Growth

ALGS's earnings are expected to grow with 18.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.16%
EPS Next 3Y18.47%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALGS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALIGOS THERAPEUTICS INC

NASDAQ:ALGS (2/21/2025, 8:00:51 PM)

After market: 19.5 +0.87 (+4.67%)

18.63

-2.22 (-10.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)03-10 2025-03-10/amc
Inst Owners46.76%
Inst Owner Change-99.49%
Ins Owners3.32%
Ins Owner Change0%
Market Cap66.88M
Analysts84.44
Price Target68.85 (269.57%)
Short Float %20.22%
Short Ratio1.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)40.03%
Min EPS beat(2)-39.56%
Max EPS beat(2)119.61%
EPS beat(4)2
Avg EPS beat(4)21.66%
Min EPS beat(4)-39.56%
Max EPS beat(4)119.61%
EPS beat(8)4
Avg EPS beat(8)12.97%
EPS beat(12)6
Avg EPS beat(12)11.81%
EPS beat(16)9
Avg EPS beat(16)8.85%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-56.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)12.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 11.15
P/FCF N/A
P/OCF N/A
P/B 1.34
P/tB 1.34
EV/EBITDA N/A
EPS(TTM)-13.27
EYN/A
EPS(NY)-12.16
Fwd EYN/A
FCF(TTM)-23.71
FCFYN/A
OCF(TTM)-23.68
OCFYN/A
SpS1.67
BVpS13.95
TBVpS13.95
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -87.03%
ROE -153.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.28%
ROA(5y)-50.89%
ROE(3y)-85.72%
ROE(5y)-70.21%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.45%
Cap/Sales 1.85%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.81
Quick Ratio 3.81
Altman-Z -10.1
F-Score3
WACC9.5%
ROIC/WACCN/A
Cap/Depr(3y)23.79%
Cap/Depr(5y)53.57%
Cap/Sales(3y)9.1%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.05%
EPS Next Y72.97%
EPS Next 2Y30.16%
EPS Next 3Y18.47%
EPS Next 5Y13.19%
Revenue 1Y (TTM)-63.41%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-60.82%
Revenue Next Year-74.03%
Revenue Next 2Y-69.6%
Revenue Next 3Y-25.99%
Revenue Next 5Y75.34%
EBIT growth 1Y-21.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.5%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y15.08%
OCF growth 3YN/A
OCF growth 5YN/A